December 18, 2014 2:43 PM ET

Pharmaceuticals

Company Overview of Dermira, Inc.

Company Overview

Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinic...

2055 Woodside Road

Suite 270

Redwood City, CA 94061

United States

Founded in 2010

18 Employees

Phone:

650-421-7200

Key Executives for Dermira, Inc.

Dermira, Inc. does not have any Key Executives recorded.

Dermira, Inc. Key Developments

Dermira, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Dermira, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, loss from operations was $7.7 million against $4.6 million last year. Net loss was $7.8 million compared to net loss for the quarter ended September 30, 2013 of $4.7 million. Net loss per basic and diluted share was $8.66 against $5.57 last year. For the nine months, loss from operations was $24.9 million against $15.6 million last year. Net loss was $25.1 million compared to net loss of $15.6 million last year. Net loss per basic and diluted share was $27.93 against $19.40 last year.

Dermira, Inc.(NasdaqGS:DERM) added to NASDAQ Composite Index

Dermira, Inc. will be added to the NASDAQ Composite Index.

Dermira, Inc. Auditor Raises 'Going Concern' Doubt

Dermira, Inc. filed its Annual on Aug 27, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
Scion Pharmaceuticals, Inc. United States
Barrier Therapeutics, Inc. United States
Efficas, Inc. United States
McNeil Consumer Pharmaceuticals Co United States
CRESCEL LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 19, 2014
--
Private Placement
August 15, 2014
--
Private Placement
July 3, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dermira, Inc., please visit www.dermira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.